NCT06907849Enrolling by invitationPhase 2
124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome
PET/CT Imaging Of Subjects With Lumbar Spinal Stenosis Or Carpal Tunnel Syndrome Using Amyloid-Reactive Peptide 124I-Evuzamitide
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
This clinical trial will use the amyloid-binding radiotracer, 124I-evuzamitide, to potentially detect amyloid, in the heart and elsewhere, in patients who have a history of lumbar spinal stenosis and/or carpal tunnel syndrome.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 26 Mar 2025
- Start date
- 22 May 2025
- Primary completion date
- Mar 2027
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Diseases
- Amyloidosis
- NCT number
- NCT06907849
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- From 22 May 2025 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- History of iodine (potassium iodide) allergy.
Other
- Subjects on dialysis.
- Subjects with a confirmed diagnosis of systemic amyloidosis, other than musculoskeletal tissue.
- Inability or unwillingness to comply with the study requirements.
- Subjects taking heparin, or heparin derivatives (e.g. low molecular weight heparins) for anticoagulation.
- Inability to lie still for \~40 minutes on the PET/CT scanner.
- Other reason that would make the subject inappropriate for entry into this study.
Who the study is looking for
- Must be ≥ 60 years of age.
- Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.
- Must have a Congo red positive ligamentum flavum or tenosynovial specimen analysis after laminectomy or carpal tunnel release surgery that is visually categorized as either "extensive" amyloid load or "mild/moderate" amyloid load by an experienced reviewer.
- Those with mild/moderate amyloid load in the connective tissue who also have a history of at least one other orthopedic clinical manifestation, including, but not limited to, carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, biceps tendon rupture, and shoulder/hip/knee arthroplasty.
- Females must be non-pregnant and non-lactating.
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Tennessee Graduate School of Medicine Coordinator of this site? Confirm its status | Knoxville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.